Revenue Breakdown
Composition ()
No data
Revenue Streams
Cytosorbents Corp (CTSO) generates its revenue primarily from CytoSorb and other sales, which accounts for 100.0% of total sales, equivalent to $9.48M. Understanding this concentration is critical for investors evaluating how CTSO navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Cytosorbents Corp maintains a gross margin of 70.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -30.17%, while the net margin is -33.42%. These profitability ratios, combined with a Return on Equity (ROE) of -93.26%, provide a clear picture of how effectively CTSO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CTSO competes directly with industry leaders such as TELA and NMTC. With a market capitalization of $41.45M, it holds a significant position in the sector. When comparing efficiency, CTSO's gross margin of 70.28% stands against TELA's 67.52% and NMTC's 55.77%. Such benchmarking helps identify whether Cytosorbents Corp is trading at a premium or discount relative to its financial performance.
